{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=INT-747",
    "query": {
      "intervention": "INT-747"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 26,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=INT-747&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T18:34:37.535Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01904539",
      "title": "Hepatic Impairment Trial of Obeticholic Acid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "obeticholic acid 10 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intercept Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2013-06",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2013-10-24",
      "last_synced_at": "2026-09-03T18:34:37.535Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01904539"
    },
    {
      "nct_id": "NCT01933503",
      "title": "Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "OCA 5 mg",
          "type": "DRUG"
        },
        {
          "name": "OCA 10 mg",
          "type": "DRUG"
        },
        {
          "name": "OCA 25 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intercept Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2013-10",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2013-12-05",
      "last_synced_at": "2026-09-03T18:34:37.535Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01933503"
    },
    {
      "nct_id": "NCT05292872",
      "title": "Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Primary Biliary Cholangitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Intercept Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4577,
      "start_date": "2015-06-01",
      "completion_date": "2021-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-01-24",
      "last_synced_at": "2026-09-03T18:34:37.535Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05292872"
    },
    {
      "nct_id": "NCT02039219",
      "title": "Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcoholic Hepatitis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "10 mg Obeticholic Acid (OCA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Naga P. Chalasani",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2014-11-03",
      "completion_date": "2018-01-29",
      "has_results": true,
      "last_update_posted_date": "2020-01-28",
      "last_synced_at": "2026-09-03T18:34:37.535Z",
      "location_count": 4,
      "location_summary": "Indianapolis, Indiana • Rochester, Minnesota • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02039219"
    },
    {
      "nct_id": "NCT02654236",
      "title": "Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alcohol Consumption"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "10 mg Obeticholic Acid (OCA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Suthat Liangpunsakul",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2016-04",
      "completion_date": "2019-09",
      "has_results": true,
      "last_update_posted_date": "2023-04-25",
      "last_synced_at": "2026-09-03T18:34:37.535Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02654236"
    },
    {
      "nct_id": "NCT01865812",
      "title": "Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Biliary Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Obeticholic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intercept Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2013-12-03",
      "completion_date": "2016-09-12",
      "has_results": true,
      "last_update_posted_date": "2022-08-24",
      "last_synced_at": "2026-09-03T18:34:37.535Z",
      "location_count": 7,
      "location_summary": "La Jolla, California • Sacramento, California • Miami, Florida + 4 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01865812"
    },
    {
      "nct_id": "NCT05239468",
      "title": "Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Biliary Cholangitis"
      ],
      "interventions": [
        {
          "name": "Bezafibrate 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Bezafibrate 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Obeticholic Acid 5 mg",
          "type": "DRUG"
        },
        {
          "name": "Obeticholic Acid placebo",
          "type": "DRUG"
        },
        {
          "name": "Bezafibrate Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intercept Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2022-03-21",
      "completion_date": "2025-09-01",
      "has_results": true,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-09-03T18:34:37.535Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Coronado, California • Mission Hills, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05239468"
    },
    {
      "nct_id": "NCT02633956",
      "title": "Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "Obeticholic Acid",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intercept Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 84,
      "start_date": "2015-12-04",
      "completion_date": "2018-03-12",
      "has_results": true,
      "last_update_posted_date": "2018-06-04",
      "last_synced_at": "2026-09-03T18:34:37.535Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Rialto, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "Inverness",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02633956"
    },
    {
      "nct_id": "NCT02548351",
      "title": "Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non Alcoholic Steatohepatitis (NASH)"
      ],
      "interventions": [
        {
          "name": "Obeticholic Acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intercept Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 2477,
      "start_date": "2015-09-22",
      "completion_date": "2023-09-15",
      "has_results": true,
      "last_update_posted_date": "2024-10-01",
      "last_synced_at": "2026-09-03T18:34:37.535Z",
      "location_count": 175,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 116 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02548351"
    },
    {
      "nct_id": "NCT04939051",
      "title": "Obeticholic Acid for Prevention in Barrett's Esophagus",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Barrett Esophagus",
        "Esophageal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Esophageal Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Esophagogastroduodenoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Liver Ultrasonographic Elastography",
          "type": "PROCEDURE"
        },
        {
          "name": "Obeticholic Acid",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Administration",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-01-03",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-03T18:34:37.535Z",
      "location_count": 8,
      "location_summary": "Kansas City, Kansas • Ann Arbor, Michigan • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04939051"
    }
  ]
}